



#### 15.05.2024

To,

**BSE Limited** 

Phiroze JeeJeebhoy Towers, Dalal Street, Fort, Mumbai – 400 001 Scrip Code: 543318 **National Stock Exchange of India Limited** 

Exchange Plaza, Plot no. C/1, G Block, Bandra-Kurla Complex Bandra (E), Mumbai - 400 051

**Trading Symbol: CLEAN** 

**Subject: Investor Presentation.** 

Dear Sir/Madam,

In accordance with Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Financial Results presentation for quarter and year ended 31st March, 2024 is enclosed.

The aforesaid presentation is also available on the Company's website.

You are requested to take the same on record.

Thanking You.

For Clean Science and Technology Limited

Mahesh Kulkarni Company Secretary

Encl: As above





# Clean Science and Technology Ltd.

**Investor Presentation** 



This investor presentation has been prepared by Clean Science and Technology Limited ("CSTL") and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied, should not be deemed to constitute an offer.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such information or opinions contained herein. The information contained in this presentation is only current as of its date. Certain statements made in this presentation may not be based on historical information or facts and may be "forward-looking statements", including those relating to the general business plans and strategy of Clean Science and Technology, its future financial condition and growth prospects, future developments in its industry and its competitive and regulatory environment, and statements which contain words or phrases such as 'will', 'expected to', 'horizons of growth', 'strong growth prospects', among many others, or similar expressions or variations of such expressions. These forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results, opportunities and growth potential to differ materially from those suggested by the forward-looking statements.

Clean Science and Technology Limited may alter, modify, or otherwise change in any manner, the content of this presentation, without obligation to notify any person of such revision or changes. This presentation cannot be copied and disseminated in any manner.






# Q4 FY 2024 & FY2024 Update

### **Q4 FY24 UPDATE**

Volume led annual and sequential growth in revenue; EBITDA margins continue to be robust





CAPEX & BUSINESS UPDATE

- ➤ Incurred total capex of ~ Rs. 235 crores during FY2024, including investment in subsidiary of Rs. 215 crores
- > Clean Fino-Chem Limited (CFCL) commercialized during March 2024
- > Board has recommended final dividend of Rs. 3 per share

### Q4 FY24 and FY24 P&L OVERVIEW - STANDALONE

Progressive recovery in revenue continues; steady profitability margins for the quarter and full year





| P&L (INR Crore)          | Q4 FY2024 | Q3 FY2024 | Q-o-Q (%) | Q4 FY2023 | Y-o-Y (%) | FY 2024 | FY 2023 | Y-o-Y (%) |
|--------------------------|-----------|-----------|-----------|-----------|-----------|---------|---------|-----------|
| Sale of products         | 222.2     | 192.3     | 16%       | 214.4     | 4%        | 777.8   | 926.5   | (16)%     |
| Other operating income   | 3.2       | 2.4       |           | 2.4       |           | 11.5    | 9.3     |           |
| Total Revenue            | 225.4     | 194.7     | 16%       | 216.9     | 4%        | 789.4   | 935.8   | (16)%     |
| Raw material expenses    | 76.3      | 64.6      | 18%       | 64.1      | 19%       | 275.4   | 326.0   | (15)%     |
| Raw material %           | 34.4%     | 33.6%     |           | 29.9%     |           | 35.4%   | 35.2%   |           |
| Other operating expenses | 50.3      | 43.7      | 15%       | 47.4      | 6%        | 176.7   | 207.2   | (15)%     |
| EBITDA                   | 98.7      | 86.4      | 14%       | 105.4     | (6)%      | 337.2   | 402.6   | (16)%     |
| EBITDA %                 | 44.4%     | 44.9%     |           | 49.1%     |           | 43.4%   | 43.5%   |           |
| Depreciation expenses    | 11.0      | 11.2      |           | 9.8       |           | 43.8    | 35.8    |           |
| Finance costs            | 0.0       | 0.0       |           | 0.1       |           | 0.8     | 0.1     |           |
| Other Income             | 13.4      | 7.5       | 78%       | 12.4      | 8%        | 38.4    | 38.8    |           |
| Profit before tax (PBT)  | 100.6     | 82.7      | 22%       | 107.9     | (7)%      | 331.0   | 405.4   | (18)%     |
| PBT %                    | 45.3%     | 43.0%     |           | 50.3%     |           | 42.5%   | 43.8%   |           |
| Profit after tax (PAT)   | 74.8      | 62.4      | 20%       | 80.9      | (8)%      | 247.7   | 303.5   | (18)%     |
| PAT%                     | 33.7%     | 32.5%     |           | 37.7%     |           | 31.8%   | 32.8%   |           |

### **REVENUE PROFILE -FY 2024**

Contribution from newer products increased







- Performance segment profile diversified with addition of new products (HALS 770 and 701), however, realization impacted the growth
- Pharma and Agro segment degrowth was primarily Guaiacol led which recovered in H2; DCC contributed positively to the growth
- FMCG segment contributed positively to the growth; growth was volume led

- Domestic market share improvement was led by new products
- Revenue share of Americas and Europe remained steady
- China share improved during H2 FY2024

### **FY24 BALANCE SHEET OVERVIEW - STANDALONE**

Healthy cash balance despite funding largest capex over last 2 years and increased payout ratio



| In INR Crore                  | As at                  | As at<br>31-March-2023 |  |  |  |
|-------------------------------|------------------------|------------------------|--|--|--|
| III INK CIOIE                 | 31-March-2024          |                        |  |  |  |
|                               | Assets                 |                        |  |  |  |
| Non-current assets            |                        |                        |  |  |  |
| Fixed Assets                  | 396.6                  | 422.1                  |  |  |  |
| Capital work-in-progress      | 1.7                    | 4.1                    |  |  |  |
| Right of use asset            | 3.8                    | 3.9                    |  |  |  |
| Other non-current assets      | 377.4                  | 151.5                  |  |  |  |
| Total non-current assets      | 779.7                  | 581.6                  |  |  |  |
| Current assets                |                        |                        |  |  |  |
| Inventories                   | 110.5                  | 108.8                  |  |  |  |
| Investments                   | 292.5                  | 281.7                  |  |  |  |
| Trade receivables             | 161.8                  | 147.7                  |  |  |  |
| Cash and bank balances        | 9.0                    | 12.4                   |  |  |  |
| Other current assets          | 16.9                   | 26.5                   |  |  |  |
| Total current assets          | 590.8                  | 577.1                  |  |  |  |
| Total assets                  | 1,370.5                | 1,158.7                |  |  |  |
|                               | Equity and Liabilities |                        |  |  |  |
| Net-worth                     | 1,215.5                | 1,018.8                |  |  |  |
| Non-current liabilities       |                        |                        |  |  |  |
| Borrowings                    | -                      | -                      |  |  |  |
| Provisions                    | 0.6                    | 0.6                    |  |  |  |
| Other non-current liabilities | 33.6                   | 26.5                   |  |  |  |
| Total non-current liabilities | 34.2                   | 27.0                   |  |  |  |
| Current liabilities           |                        |                        |  |  |  |
| Trade payables                | 93.7                   | 80.4                   |  |  |  |
| Other current liabilities     | 26.9                   | 32.5                   |  |  |  |
| Total current liabilities     | 120.6                  | 112.9                  |  |  |  |
| Total equity and liabilities  | 1,370.5                | 1,158.7                |  |  |  |

| Key ratios                 | FY 2024 | FY 2023 |
|----------------------------|---------|---------|
| Return on Equity           | 20.4%   | 29.8%   |
| Return on Capital Employed | 38.7%   | 49.8%   |





## **Corporate presentation**

### **CLEAN SCIENCE AND TECHNOLOGY AT A GLANCE**

A brief Introduction about the Company





- > One of the fastest growing and among the most profitable fine and specialty chemical companies globally. Among the largest manufacturers of certain specialty chemicals developed in-house.
- > Among the few global organizations focused on developing ingenious technologies with unique, innovative, sustainable, and cost-effective catalytic manufacturing processes


















### **COMPANY EVOLUTION**

Continuous R&D and Innovation has led to new product launches on a consistent basis



| YEAR                 | 2006 | 2009 | 2011 | 2014 | 2018 | 2020 | 2021 | 2022 | 2023 |
|----------------------|------|------|------|------|------|------|------|------|------|
| REVENUES (INR Crore) | -    | 1    | 19   | 120  | 241  | 419  | 512  | 685  | 936  |

2018

> Technocrat Promoters collaborated to develop novel, clean and sustainable chemical processes Aligned to the philosophy,

Company was named as Clean Science and Technology

2009

2006

Commercialized unique catalytic technology to manufacture MEHQ and Guaiacol

Commercialized unique vapour phase route to manufacture Anisole

2014

**Backward integration** for flagship products

unique catalytic manufacture 4-MAP

Commercialized

technology to

2011

Commercialized unique catalytic forward integration to manufacture BHA

manufacture P-BQ and TBHQ 2020

Commercialized unique

technology to manufacture DCC

Commercialized plant to

2021

Expanded capacity of

MEHQ, Guaiacol and BHA by 50%

2022

Commercialized plant to

2023

manufacture HALS 770 & 701





### DIVERSIFIED PRODUCT PROFILE SERVING CRITICAL END-USER INDUSTRIES

Largest capacity in the world for our flagship products



### PERFORMANCE CHEMICALS





### **MEHQ** (Monomethyl Ether of Hydroquinone)

- Used as polymerization inhibitor in acrylic acids, acrylic esters, super absorbent polymers (diapers and sanitary pads)
- Pre-cursor for agrochemical industry



in World & India



### **BHA** (Butylated Hydroxy Anisole)

Used as anti-oxidant in food and feed industry



in World & India



### **AP** (Ascorbyl Palmitate)

> Used in infant food formulations, breakfast cereals and cosmetics



in World & India



### TBHQ (Tertiary Butyl Hydroquinone)

> Stabilizer in oil industry



in World & India



### **HALS** (Hindered Amine light Stabilizers)

- > HALS 701 is used in water treatment
- > HALS 770 is used for UV stabilization in a variety of polymers



in India

### PHARMA AND AGRO INTERMEDIATES





### Guaiacol

- Pre-cursor to manufacture APIs for cough syrup (pharma industry)
- Key raw material to produce Vanillin



in World



in India



### **DCC** (Dicyclohexyl Carbodiimide)

Used as reagent in anti-retroviral



in World



in India



### p-BQ (Para Benzoquinone)

> Intermediate in agrochemical industry



in World



in India

### FMCG CHEMICALS





### 4-MAP (4-Methoxy Acetophenone)

Used in UV blocker in sunscreens (cosmetics industry)



in World & India



### **Anisole**

- Precursor to perfumes, insect pheromones, pharmaceuticals
- Majority of Anisole produced is used for captive consumption



in World & India

### **KEY DIFFERENTIATORS THAT ADD VALUE**

Unique benefits that set our business apart from competition





### **INNOVATION**

Strategic process innovation and new product development driven by a strong in-house R&D team



### **GLOBAL LEADERS**

Among the largest producers globally of critical specialty chemicals with diversified applications



### PREFERRED PARTNER OF CHOICE

Strong and long term relationships with a well diversified marquee customer base



### **STATE-OF-THE-ART**

Multiple, automated manufacturing facilities with zero liquid discharge and strong focus on EHS



### **PROMOTERS**

Technocrat promoters supported by an experienced workforce with extensive domain knowledge



### **FORMULATION**

Unique, innovative, sustainable and costeffective catalytic manufacturing process



### **STATISTIC**

Strong and consistent financial performance



### **Research and Development team's focus areas**



Enhance our existing catalyst systems to further optimize yield and selectivity



Expand product portfolio in the performance chemical segment



Develop products with high demand which are produced by limited manufacturers globally

### COMPETENCY ACROSS ~10+ CHEMISTRIES

Hydroxylation Hydrogenation

Grignard Reaction Chlorination

Oxidation Polymeric Reaction

Alkylation Esterification

Catalysis Halogenation

### BACKED BY DIVERSE TECHNOLOGY

Continuous flow reaction

Vapour phase reaction

Tri-phasic reaction

Fixed bed reaction

### LED BY EXEMPLARY R&D TEAM

March 2018 March 2023

**1** PhD **7** PhD

22 scientists 90 scientists

**4** independent R&D labs with pilot facility

### **COHESIVE AND TECHNOCRAT PROMOTERS**

Strong visibility on longevity of Promoters' engagement in the business





ASHOK BOOB
Managing Director
Key functions: Projects,
Manufacturing Capabilities

Over **27** years of work experience in the chemical industry.

Previously worked as an Executive Director at Mangalam Drugs and Organics Ltd.

Bachelor of Chemical Engineering – Institute of Chemical Technology, Mumbai, India (formerly known as UDCT)



SIDDHARTH SIKCHI Executive Director Key functions: Marketing, R&D

Over **17** years of experience in the chemical industry.

Bachelor of Chemical Technology – Institute of Chemical Technology, Mumbai, India (formerly known as UDCT)

Master of Science in Organic Chemistry – University of Manitoba, Canada.



KRISHNA BOOB
Executive Director
Key functions: Public relations, Purchase

Over **22** years of expertise in the chemical industry.

Previously, worked as an Director at Mangalam Drugs and Organics Ltd.

**Bachelor of Pharmacy** – University of Mumbai, India



PARTH MAHESHWARI
President
Key functions:
Business operations

Over **7** years of work experience in the chemical industry.

**Bachelor of Chemical Engineering –** Pune University, India

MBA - Babson College, USA

### ROBUST CORPORATE GOVERNANCE

Distinguished Board of Directors and reputed financial market participants underscore sound governance



### PROFILE OF NON-EXECUTIVE, INDEPENDENT DIRECTORS ON THE BOARD



PRADEEP RATHI

Chairman and Non-Executive Director B.Sc, M.S. (MIT, USA) MBA (Columbia, USA)

Chairman - Sudarshan Chemicals



PROF. G. D. YADAV

Non-Executive, Independent Director

B.Chem. Engineering, Ph.D Technology



### Sanjay Kothari

Non-Executive, Non-Independent Director

B.Com (University of Calcutta)
Member of ICAI and ICSI



#### **KEVAL DOSHI**

Non-Executive, Independent Director B.Com. (University of Mumbai) Member of ICAI

Erstwhile Partner at Ernst & Young LLP



#### MADHU DUBHASHI

Non-Executive, Independent Director

PG in Business Administration (IIM Ahmedabad)

### Balanced board ensures transparency and accountability

Highly experienced and diversified non-executive directors, are also board members of other reputed listed companies

Mr. Pradeep Rathi, Prof. G. D. Yadav, and Mr. Sanjay Kothari have been Board members for over a decade

More than 1/3rd Board members are independent Non-executive directors form majority of all committees

Separate Chairman & Managing Director

### CONTINUED COMMITMENT TOWARDS SUSTAINABILITY AND ESG

Sustainability and ESG initiatives are embedded in our long term growth strategy





### **ENVIRONMENT EMPATHY (E)**

- > Utilize resources efficiently, reduce waste and minimise emissions as part of our sustainability commitment
- > We aim to plant more than 11,000 trees over the next three years
- > 17.4 MW of solar capacity. Share of renewable energy in power consumption at 55%.
- > Reduced fresh water consumption by 14% and GHG emissions (Scope 1/Scope 2) by 7% over the last 3 years



### **SOCIAL RESPONSIBILITY (S)**

- > Total contribution towards CSR activities during last 3 years is INR 12.3 crore
- > Health, safety and wellbeing of employees is integral part of all our activities
- Continual improvement in safety measures have resulted in zero casualties till date
- Our key initiatives include regular safety audits, safety trainings and health checkups among others



### **CORPORATE GOVERNANCE (G)**

- ➤ Internal Auditor Big 4 (PwC India)
- > Highly experienced, competent and balanced Board driving corporate ethics
- Long term & short term ratings by CRISIL are AA- (Stable) and A1+ respectively
- > No auditor qualification or restatements of financial statements till date

#### FOCUS ON SUSTAINABILITY



GreenCo Certificate



Reduce



Together for

Sustainability



Recycle

ecovadis

**Ecovadis** 



Reuse

#### **FOCUS ON CSR ACTIVITIES**



Vocational Skills

Healthcare



**Environment** Sustainability



Medical Relief



Education

### **FOCUS ON GOVERNANCE**



Audit Committee



**Nomination And** Remuneration Committee



Relationship Committee



**Risk Management** Committee

**Corporate Social Responsibility Committee** 

### ADVANCED MANUFACTURING FACILITIES DESIGNED BY IN-HOUSE ENGINEERING TEAM

3 independent functional units at Kurkumbh Industrial Area, Maharashtra with dedicated lines for each product





### **UNIT 1**

7 plants
Total area – 30,000 sq.m

NO plant closure notice received from pollution control board

### UNIT 2

4 plants
Total area – 23,337 sq.m



All Units are **ISO 9001**, **ISO 14001** and **ISO 45001** certified

Sustainable processes ensures **zero liquid discharge (ZLD)** facility



### **UNIT 3**

**5** plants Total area – **40,343 sq.m** 





- Multiple dedicated plants for key products. To that extent, each plant is immune to challenges in other plants
- > Independent plants for catalysts
- Each unit has a separate R&D facility, warehouse, engineering and utility section
- ➤ Construction for 100% owned subsidiary Clean Fino-Chem Limited (CFCL) on track.


### STRONG FINANCIAL PERFORMANCE


Resilient performance demonstrated over business cycles maintaining a debt free balance sheet
















Note: RoCE = EBIT (ex. Other income)/capital employed (Gross FA + Working Capital); RoNW = PAT as % of net worth

Net Fixed Asset Turnover = Revenue from Operations/Net Fixed Assets; Net Fixed Assets include Property, plant and equipment, Right-of-use asset & Intangible Assets
(Nos. in INR crore)



### FOCUS ON ESG AND SUSTAINABILITY

Capitalise on our core philosophy of clean and green chemistry to address opportunities arising from the shift in demand to sustainable chemistry.

STRENGTHEN IN INDIA

Focus on import substitution

export customers across

geographies

AND EXPAND GLOBALLY

opportunities in India and add new



### SIGNIFICANT GREENFIELD CAPEX

Planned capex on track for commercialising new series of products

### ADD NEW COMPETENCIES

Adding new chemistries and process technologies with significant focus on high value products that limited manufacturers produce globally

### **NEW PRODUCT DEVELOPMENT**

Strategic investments towards developing products for new range of speciality chemicals that find applications across diverse and fast growing end user industries



## **THANK YOU**

### For further information, please contact:

### **PRATIK BORA**

Email: pratik@cleanscience.co.in



**Clean Science and Technology Limited** 

Website: https://www.cleanscience.co.in/